key: cord-0715547-uc9x5t8f authors: Al‐Ahmad, Mona; Al‐Rasheed, Mona; Shalaby, Neveen Abo Bakr title: Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine date: 2021-05-18 journal: EJHaem DOI: 10.1002/jha2.219 sha: 3208113e676bed6d6ac1c990d10cd3f0037d0adc doc_id: 715547 cord_uid: uc9x5t8f Acquired thrombotic thrombocytopenic purpura is characterized by the microvascular aggregation of platelets and microangiopathic hemolytic anemia causing ischemia of multiple organs including the brain mainly and less likely the kidney and the heart. The disease is caused by severe reduction in the activity of ADAMTS 13 due to presence of inhibitory antibodies. We report a case of a 37-year-old man with acquired thrombotic thrombocytopenic purpura (aTTP) that developed after AstraZeneca-Oxford COVID -19 vaccination. He presented with progressive dizziness, fatigue, and headache associated with exertional shortness of breath and palpitation 10-15 days after vaccination. Laboratory investigation showed hemolytic anemia, thrombocytopenia, and blood smear showed fragmented erythrocytes. aTTP was diagnosed based on the clinical presentation and was confirmed later by low level of ADAMTS13 activity and the presence of inhibitory antibodies. He was successfully treated using eight sessions of plasma exchange, corticosteroids, and rituximab. To our knowledge, this case appears to represent the first report of aTTP following coronavirus disease 2019 (COVID-19) vaccination. A 37-year-old Kuwaiti gentleman presented to the emergency department of a general hospital complaining of a gradually progressive dizziness, fatigue, and headache associated with exertional shortness of breath and palpitation for 1 week, and he also noticed dark urine and red spots over his extremities 1 day prior to admission. The patient is a heavy smoker who is complicated by secondary polycythemia for which he donates blood once every year. ADAMTS13 activity was 2.6% and antibodies assay was positive (these tests were sent before the start of plasma exchange and the results were received with 3 days). Chest X-ray was done with no obvious pathology. Patient Plasma exchange was started immediately planned for daily exchange with 1.5 plasma volume. Methylprednisolone at a dose of 1 g intravenous was started for 3 days initially and was followed by prednisolone 1 mg/kg/day. Rituximab 375 mg/m 2 was added as once weekly infusion for 4 weeks. The patient received total of eight sessions of plasma exchange while in hospital. The patient symptomatology has improved, and his blood investigations were back to normal with LDH of 199 IU/L, platelet count of 340 × 10 9 /L, and Hg level of 123 g/L on discharge. The patient had completed the remaining of the four doses of rituximab as an outpatient and he had a rapid taper off the steroid dose over 3 weeks. aTTP is a rare disease with an incidence of 3 to 10 cases per million adult per year [1] . It is caused by severe reduction in the activity of Von Willebrand factor cleaving metalloprotease (ADAMTS13). This is, in turn, caused by the presence of inhibitory antibodies. The disease is characterized by small vessel platelet-rich microthrombi that results in MAHA, thrombocytopenia, and thrombosis. The historical pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, and renal insufficiency appears obsolete, as these symptoms were present in <10% of patients with aTTP [2] . The symptoms of the disease initially include fatigue, shortness of breath, abdominal pain, nausea, vomiting, and petechial rash or minor bleeding. As the disease progresses and becomes more aggressive, the dis- Plasma infusion can be given as a temporary measure for patient with an expected delay in initiation TPE. The addition of immunosuppressive agent including corticosteroid and rituximab has improved the outcome of the aTTP and it has decreased the duration of TPE. These agents are given to patient with intermediate to high PLASMIC score [12] . Vaccination in general is an important part of preventative medicine and COVID-19 vaccination is proven to reduce morbidity and mortality of the disease. Rarely vaccination, especially against viral infection, has been associated with autoimmune pathology including aTTP. Three case reports have linked influenza vaccine with aTTP [13] [14] [15] : one case report has linked pneumococcal vaccination with aTTP [16] , one case report has described aTTP after H1N1 vaccination [17] , and one case report of aTTP shortly after Rabies vaccination [18] . To our knowledge, this case report is the only case showing a possible connection of AstraZeneca-Oxford COVID-19 vaccination to aTTP. The patient had no prior history of any form of thrombocytopenia or other hematological disorder, and no medication apart from the vaccination. Screening for secondary causes of aTTP was all negative. This report suggests the potential, but not proven role, of AstraZeneca-Oxford COVID-19 vaccination in the pathogenesis of aTTP. Vaccinerelated aTTP, like other forms of aTTP, can be successfully treated by plasmapheresis, corticosteroids, and rituximab. The authors have no conflicts of interest to declare MA and EJ initiated and coordinated the development of the paper and worked on data collection, analysis, and writing up the paper. NA and JN analyzed and interpreted the results and helped in writing up introduction. NA, JN, and EJ were major contributors in writing up the manuscript. All authors read and approved the final manuscript. Mona Al-Ahmad https://orcid.org/0000-0003-2950-5363 Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 Pulmonary involvement in patients with thrombotic thrombocytopenic purpura Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients ISTH guidelines for treatment of thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura after influenza vaccination Refractory thrombotic thrombocytopenic purpura following influenza vaccination Thrombotic thrombocytopenic purpura following influenza vaccination-a brief case report Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination Schwerste thrombotischthrombozytopenische Purpura (TTP) nach H1N1-Vakzinierung Rabies vaccineassociated thrombotic thrombocytopenic purpura Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-oxford COVID-19